Follow Zymeworks to never miss an important update.
Zymeworks shared results from its early-stage study of ZW191, a drug designed to deliver chemotherapy directly to cancer cells while sparing healthy tissue. The data, presented at the ESMO Congress in Madrid, focused on finding the right dose for patients with tumors that express a specific protein called Folate Receptor Alpha.
This early data is a key step in proving the drug is safe and effective enough to move into larger trials. While ZW191 is still years from reaching the market, successful early results help validate the company's internal research pipeline as it shifts toward becoming a more diversified biotech business.
Source: GlobeNewsWire
Zymeworks entered a major agreement with Roche to develop ZW209, a drug candidate that helps the immune system's T-cells find and attack specific tumor cells. Under the deal, Roche will pay Zymeworks $55 million upfront once antitrust hurdles are cleared, plus another $40 million when the next phase of clinical trials begins. Zymeworks could eventually receive up to $718 million more if the drug hits specific research and sales targets.
This deal is a significant win for Zymeworks' strategy of using partner money to fund its expensive drug development. By handing off the heavy costs of late-stage trials and manufacturing to a giant like Roche, Zymeworks secures immediate cash and high-upside royalties while reducing the financial risk if the drug fails to reach the market.
Source: 8-K filing
Jefferies raised its price target for Zymeworks from $50 to $52 while keeping a positive rating on the stock. This move follows a week of active analyst coverage where Truist Financial also raised its target to $34, bringing the average analyst target across the market to $43. While these target changes are small, they reflect growing confidence in the company's recent acquisition of revenue-generating assets and its ability to land major partnerships like the one signed with Roche this week.
Source: Jefferies
Zymeworks named Suzanne Monahan as Senior Vice President and General Manager for its Theravance Biopharma business. She will report directly to the CEO and lead the commercial strategy for the company's newly acquired products.
This hire is a practical step in Zymeworks' transition from a research-only firm to one that actually sells drugs. Monahan's job will be to maximize the cash flow from these new assets, which the company needs to fund its own internal drug pipeline without having to constantly sell more stock to raise money.
Source: GlobeNewsWire
Management has struggled to set a reliable bar lately, with four straight misses suggesting the business is moving slower than their own forecasts anticipated.
| Expectation | |
|---|---|
| EPS | $2.26 |
| Revenue | $227M |